2001
DOI: 10.1067/mjd.2001.117850
|View full text |Cite
|
Sign up to set email alerts
|

The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
118
0
1

Year Published

2002
2002
2017
2017

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 164 publications
(122 citation statements)
references
References 0 publications
3
118
0
1
Order By: Relevance
“…Psoriasis lesions, nonlesional skin, and normal skin were obtained from patients and normal volunteers under an approved protocol (The Rockefeller University). Experiments were conducted on samples obtained from a previously published placebo-controlled clinical trial with efalizumab (n ϭ 65) (Genentech and Xoma) (5). Patients treated with efalizumab showed greater clinical improvement and reduction of epidermal hyperplasia in skin lesions compared to placebo treatment.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Psoriasis lesions, nonlesional skin, and normal skin were obtained from patients and normal volunteers under an approved protocol (The Rockefeller University). Experiments were conducted on samples obtained from a previously published placebo-controlled clinical trial with efalizumab (n ϭ 65) (Genentech and Xoma) (5). Patients treated with efalizumab showed greater clinical improvement and reduction of epidermal hyperplasia in skin lesions compared to placebo treatment.…”
Section: Methodsmentioning
confidence: 99%
“…Evidence for this view includes (i) a marked increase in the number of T cells in diseased skin, (ii) the differentiation characteristics of these T cells, including a skin-homing memory phenotype, a T helper 1͞Tc1 predominance, and oligoclonality, and (iii) the disease improvements brought about by a variety of T cell-targeted immunosuppressive agents (4)(5)(6). T cell functions are often controlled by dendritic cells (DCs), and interestingly, psoriasis is characterized by the production of IL-23 by CD11c ϩ DCs in lesional skin (7).…”
mentioning
confidence: 99%
“…Etanercept verwendet (Übersicht in [1,2] [19,20]. Da diese Studien auch der Dosisfindung dienten, zeigten sich Reduktionen des PASI-Scores, die von 10 % (0,1 mg/kg KG) bis zu 47 % (1 mg/kg KG) reichten.…”
Section: Als Weiteres Medikament Zur Behandlung Der Psoriasis Wurdeunclassified
“…It binds to ICAM-1 on antigen-presenting cells and functions as an adhesion molecule. Anti-LFA1 Ab treatment elicited an improvement in psoriasis (Papp et al, 2001;Tutrone et al, 2001). …”
Section: Therapies Targeting T-cell Pathways Related To Trafficking Amentioning
confidence: 99%